Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Cash from Financing Activities (2019 - 2025)

Revolution Medicines (RVMD) has 7 years of Cash from Financing Activities data on record, last reported at $365.7 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 58.15% year-over-year to $365.7 million; the TTM value through Dec 2025 reached $621.5 million, down 35.22%, while the annual FY2025 figure was $621.5 million, 35.22% down from the prior year.
  • Cash from Financing Activities reached $365.7 million in Q4 2025 per RVMD's latest filing, up from -$1.6 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $873.8 million in Q4 2024 and bottomed at -$1.6 million in Q3 2025.
  • Average Cash from Financing Activities over 5 years is $170.3 million, with a median of $31.0 million recorded in 2021.
  • Peak YoY movement for Cash from Financing Activities: surged 106196.72% in 2023, then crashed 102.06% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at $10.7 million in 2021, then surged by 378.78% to $51.4 million in 2022, then skyrocketed by 1534.16% to $839.4 million in 2023, then increased by 4.1% to $873.8 million in 2024, then plummeted by 58.15% to $365.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $365.7 million in Q4 2025, -$1.6 million in Q3 2025, and $256.6 million in Q2 2025.